Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5003555 | 0.81 | CYP2C19 (0.36) | YTHDC1ABL1ALDH1A1KDM5B | |
| SCHEMBL12779634 | 0.80 | ADORA2A (0.35) | ADORA2AADORA1ABL1 | |
| SCHEMBL31138557 | 0.78 | YTHDC1 (0.41) | YTHDC1ABL1ALDH1A1LMNAPOLB | |
| SCHEMBL31638156 | 0.77 | FLT3 (0.33) | YTHDC1ABL1KDM5B | |
| SCHEMBL31714802 | 0.76 | ADORA2A (0.37) | ADORA2AADORA1 | |
| SCHEMBL31714881 | 0.76 | LRRK2 (0.40) | ADORA2AADORA1 | |
| SCHEMBL31715025 | 0.74 | LRRK2 (0.34) | ADORA2AADORA1ALDH1A1 | |
| SCHEMBL22836326 | 0.74 | YTHDC1 (0.34) | YTHDC1ABL1ALDH1A1LMNAPOLB | |
| SCHEMBL25189871 | 0.73 | ALDH1A1 (0.38) | YTHDC1ABL1ALDH1A1LMNAPOLB | |
| SCHEMBL56169 | 0.70 | YTHDC1 (0.46) | YTHDC1ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2123654-A1 | PYRAZOLOPYRIMIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2123654-A1 | PYRAZOLOPYRIMIDINE COMPOUND | Taisho Pharmaceutical Co. Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | SYK, LCK, FYN | YTHDC1 3998/4885ADORA2A 4238/4885ADORA1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.